

# Ariel E Feldstein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1054075/publications.pdf>

Version: 2024-02-01

160  
papers

26,985  
citations

10986

71  
h-index

5988

160  
g-index

165  
all docs

165  
docs citations

165  
times ranked

28236  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pyroptosis in Steatohepatitis and Liver Diseases. <i>Journal of Molecular Biology</i> , 2022, 434, 167271.	4.2	17
2	NOD-like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH. <i>Hepatology</i> , 2022, 76, 727-741.	7.3	30
3	Protein and miRNA profile of circulating extracellular vesicles in patients with primary sclerosing cholangitis. <i>Scientific Reports</i> , 2022, 12, 3027.	3.3	12
4	Cell-to-Cell Communications in Alcohol-Associated Liver Disease. <i>Frontiers in Physiology</i> , 2022, 13, 831004.	2.8	9
5	A low n-6 to n-3 polyunsaturated fatty acid ratio diet improves hyperinsulinaemia by restoring insulin clearance in obese youth. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1267-1276.	4.4	8
6	Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis. <i>Gut</i> , 2021, 70, 1954-1964.	12.1	71
7	Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. <i>Journal of Hepatology</i> , 2021, 74, 156-167.	3.7	264
8	The Power of Single-Cell Analysis for the Study of Liver Pathobiology. <i>Hepatology</i> , 2021, 73, 437-448.	7.3	19
9	Mechanisms of nonalcoholic fatty liver disease and implications for surgery. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 1-17.	1.9	21
10	Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH. <i>Cell Reports</i> , 2021, 34, 108626.	6.4	164
11	Novel Mechanisms for Resolution of Liver Inflammation: Therapeutic Implications. <i>Seminars in Liver Disease</i> , 2021, 41, 150-162.	3.6	4
12	Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. <i>Seminars in Liver Disease</i> , 2021, 41, 421-434.	3.6	55
13	Feeding mice a diet high in oxidized linoleic acid metabolites does not alter liver oxylipin concentrations. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2021, 172, 102316.	2.2	1
14	Bile Acids Activate NLRP3 Inflammasome, Promoting Murine Liver Inflammation or Fibrosis in a Cell Type-Specific Manner. <i>Cells</i> , 2021, 10, 2618.	4.1	17
15	Dual role of neutrophils in modulating liver injury and fibrosis during development and resolution of diet-induced murine steatohepatitis. <i>Scientific Reports</i> , 2021, 11, 24194.	3.3	11
16	MicroRNA 223 3p Negatively Regulates the NLRP3 Inflammasome in Acute and Chronic Liver Injury. <i>Molecular Therapy</i> , 2020, 28, 653-663.	8.2	75
17	Identification of actin network proteins, talin-1 and filamin-A, in circulating extracellular vesicles as blood biomarkers for human myalgic encephalomyelitis/chronic fatigue syndrome. <i>Brain, Behavior, and Immunity</i> , 2020, 84, 106-114.	4.1	19
18	Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH. <i>Hepatology Communications</i> , 2020, 4, 1263-1278.	4.3	57

#	ARTICLE	IF	CITATIONS
19	A Low $\omega$ -6 to $\omega$ -3 PUFA Ratio (n $\omega$ -6:n $\omega$ -3 PUFA) Diet to Treat Fatty Liver Disease in Obese Youth. <i>Journal of Nutrition</i> , 2020, 150, 2314-2321.	2.9	52
20	The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis. <i>Seminars in Liver Disease</i> , 2020, 40, 298-306.	3.6	63
21	Comprehensive characterization of hepatocyte-derived extracellular vesicles identifies direct miRNA-based regulation of hepatic stellate cells and DAMP-based hepatic macrophage IL-1 $\beta$ and IL-17 upregulation in alcoholic hepatitis mice. <i>Journal of Molecular Medicine</i> , 2020, 98, 1021-1034.	3.9	32
22	ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model. <i>JCI Insight</i> , 2020, 5, .	5.0	44
23	NAFLD in children: new genes, new diagnostic modalities and new drugs. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 517-530.	17.8	199
24	Novel Drivers of the Inflammatory Response in Liver Injury and Fibrosis. <i>Seminars in Liver Disease</i> , 2019, 39, 275-282.	3.6	33
25	Extracellular vesicles, the liquid biopsy of the future. <i>Journal of Hepatology</i> , 2019, 70, 1292-1294.	3.7	46
26	NLR Family Pyrin Domain-Containing 3 Inflammasome Activation in Hepatic Stellate Cells Induces Liver Fibrosis in Mice. <i>Hepatology</i> , 2019, 69, 845-859.	7.3	100
27	Extracellular Vesicles in Liver Diseases: Meeting Report from the International Liver Congress 2018. <i>Hepatology Communications</i> , 2019, 3, 305-315.	4.3	13
28	Oxidized Derivatives of Linoleic Acid in Pediatric Metabolic Syndrome: Is Their Pathogenic Role Modulated by the Genetic Background and the Gut Microbiota?. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 241-250.	5.4	30
29	Human induced pluripotent stem cell-derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis. <i>JCI Insight</i> , 2019, 4, .	5.0	79
30	Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223. <i>Journal of Clinical Investigation</i> , 2019, 129, 4091-4109.	8.2	166
31	Extracellular vesicles in non-alcoholic and alcoholic fatty liver diseases. <i>Liver Research</i> , 2018, 2, 30-34.	1.4	53
32	Transmembrane BAX Inhibitor Motif-containing 1, a novel anti-inflammatory approach for nonalcoholic steatohepatitis treatment. <i>Hepatology</i> , 2018, 67, 438-441.	7.3	6
33	NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice. <i>Hepatology</i> , 2018, 67, 736-749.	7.3	214
34	Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects. <i>Pediatric Diabetes</i> , 2018, 20, 41-47.	2.9	6
35	Ethanol and unsaturated dietary fat induce unique patterns of hepatic $\omega$ -6 and $\omega$ -3 PUFA oxylipins in a mouse model of alcoholic liver disease. <i>PLoS ONE</i> , 2018, 13, e0204119.	2.5	25
36	Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis. <i>Journal of Immunology</i> , 2018, 201, 3017-3035.	0.8	69

#	ARTICLE	IF	CITATIONS
37	Complex Network of NKT Cell Subsets Controls Immune Homeostasis in Liver and Gut. <i>Frontiers in Immunology</i> , 2018, 9, 2082.	4.8	35
38	Liquid biopsy for liver diseases. <i>Gut</i> , 2018, 67, 2204-2212.	12.1	79
39	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis. <i>PLoS ONE</i> , 2018, 13, e0202226.	2.5	12
40	Effects of diets enriched in linoleic acid and its peroxidation products on brain fatty acids, oxylipins, and aldehydes in mice. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2018, 1863, 1206-1213.	2.4	27
41	Oxidized linoleic acid metabolites induce liver mitochondrial dysfunction, apoptosis, and NLRP3 activation in mice. <i>Journal of Lipid Research</i> , 2018, 59, 1597-1609.	4.2	60
42	Triggering and resolution of inflammation in NASH. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 349-364.	17.8	560
43	Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation. <i>Journal of Molecular Medicine</i> , 2018, 96, 575-583.	3.9	23
44	Treating nonalcoholic steatohepatitis in children: Not a cinch task. <i>Hepatology</i> , 2017, 65, 1407-1409.	7.3	1
45	NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. <i>Journal of Hepatology</i> , 2017, 66, 1037-1046.	3.7	738
46	NASH-related cirrhosis: An occult liver disease burden. <i>Hepatology Communications</i> , 2017, 1, 84-86.	4.3	12
47	Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis. <i>Scientific Reports</i> , 2017, 7, 3491.	3.3	68
48	Inflammasomes in Liver Fibrosis. <i>Seminars in Liver Disease</i> , 2017, 37, 119-127.	3.6	143
49	Novel therapeutic strategies targeting ASK1 in NASH. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 329-330.	17.8	32
50	Dietary Linoleic Acid and Its Oxidized Metabolites Exacerbate Liver Injury Caused by Ethanol via Induction of Hepatic Proinflammatory Response in Mice. <i>American Journal of Pathology</i> , 2017, 187, 2232-2245.	3.8	55
51	Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. <i>Hepatology</i> , 2017, 65, 475-490.	7.3	91
52	TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies. <i>Journal of Clinical Investigation</i> , 2017, 127, 4488-4497.	8.2	126
53	Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis. <i>PLoS ONE</i> , 2017, 12, e0172575.	2.5	49
54	Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis. <i>Diabetes and Metabolism Journal</i> , 2016, 40, 1.	4.7	53

#	ARTICLE	IF	CITATIONS
55	Circulating adipocyte-derived extracellular vesicles are novel markers of metabolic stress. <i>Journal of Molecular Medicine</i> , 2016, 94, 1241-1253.	3.9	117
56	Hepatocyte mitochondrial DNA released in microparticles and toll-like receptor 9 activation: A link between lipotoxicity and inflammation during nonalcoholic steatohepatitis. <i>Hepatology</i> , 2016, 64, 669-671.	7.3	13
57	Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study. <i>Hepatology</i> , 2016, 63, 117-125.	7.3	106
58	Fatty liver in adolescents: Mechanisms, clinical features and therapy. <i>Journal of Hepatology</i> , 2016, 65, 1258-1260.	3.7	2
59	Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2016, 64, 699-707.	3.7	38
60	Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis. <i>Seminars in Liver Disease</i> , 2016, 36, 027-036.	3.6	35
61	Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1161-1171.	3.4	68
62	Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1087-1095.	3.4	53
63	Soluble IgM links apoptosis to complement activation in early alcoholic liver disease in mice. <i>Molecular Immunology</i> , 2016, 72, 9-18.	2.2	16
64	Innate Immunity and Inflammation in NAFLD/NASH. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1294-1303.	2.3	332
65	Microparticles Release by Adipocytes Act as "Find-Me" Signals to Promote Macrophage Migration. <i>PLoS ONE</i> , 2015, 10, e0123110.	2.5	82
66	Redox nanoparticles as a novel treatment approach for inflammation and fibrosis associated with nonalcoholic steatohepatitis. <i>Nanomedicine</i> , 2015, 10, 2697-2708.	3.3	46
67	Arginase 2 deficiency results in spontaneous steatohepatitis: A novel link between innate immune activation and hepatic de novo lipogenesis. <i>Journal of Hepatology</i> , 2015, 62, 412-420.	3.7	66
68	Beneficial effects of mineralocorticoid receptor blockade in experimental nonalcoholic steatohepatitis. <i>Liver International</i> , 2015, 35, 2129-2138.	3.9	48
69	Circulating microRNAs: Emerging Biomarkers of Liver Disease. <i>Seminars in Liver Disease</i> , 2015, 35, 043-054.	3.6	72
70	The Evaluation of Hepatic Fibrosis Scores in Children with Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1440-1447.	2.3	75
71	Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2353-2359.	2.3	24
72	Lipid-Induced Hepatocyte-Derived Extracellular Vesicles Regulate Hepatic Stellate Cells via MicroRNA Targeting Peroxisome Proliferator-Activated Receptor- $\beta$ . <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 646-663.e4.	4.5	170

#	ARTICLE	IF	CITATIONS
73	Endoscopic treatment of pediatric post-transplant biliary complications is safe and effective. <i>Digestive Endoscopy</i> , 2015, 27, 505-511.	2.3	15
74	Transient Receptor Potential Vanilloid 1 Gene Deficiency Ameliorates Hepatic Injury in a Mouse Model of Chronic Binge Alcohol-Induced Alcoholic Liver Disease. <i>American Journal of Pathology</i> , 2015, 185, 43-54.	3.8	25
75	Etiology, outcome and prognostic factors of childhood acute liver failure in a German Single Center. <i>Annals of Hepatology</i> , 2015, 14, 722-8.	1.5	13
76	Reduced Dietary Omega-6 to Omega-3 Fatty Acid Ratio and 12/15-Lipoxygenase Deficiency Are Protective against Chronic High Fat Diet-Induced Steatohepatitis. <i>PLoS ONE</i> , 2014, 9, e107658.	2.5	47
77	Circulating Extracellular Vesicles with Specific Proteome and Liver MicroRNAs Are Potential Biomarkers for Liver Injury in Experimental Fatty Liver Disease. <i>PLoS ONE</i> , 2014, 9, e113651.	2.5	219
78	Adipocyte Cell Death, Fatty Liver Disease and Associated Metabolic Disorders. <i>Digestive Diseases</i> , 2014, 32, 579-585.	1.9	23
79	Differential regulation of inflammation and apoptosis in Fas-resistant hepatocyte-specific Bid-deficient mice. <i>Journal of Hepatology</i> , 2014, 61, 107-115.	3.7	14
80	Biomarkers of liver cell death. <i>Journal of Hepatology</i> , 2014, 60, 1063-1074.	3.7	185
81	NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. <i>Hepatology</i> , 2014, 59, 898-910.	7.3	716
82	Oxidized Fatty Acids: A Potential Pathogenic Link Between Fatty Liver and Type 2 Diabetes in Obese Adolescents?. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 383-389.	5.4	36
83	OxNASH Score Correlates with Histologic Features and Severity of Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1617-1624.	2.3	40
84	Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2014, 60, 167-174.	3.7	223
85	Lipidomic Profiling of Bile in Distinguishing Benign From Malignant Biliary Strictures: A Single-Blinded Pilot Study. <i>American Journal of Gastroenterology</i> , 2014, 109, 895-902.	0.4	31
86	Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 1542-1552.	3.4	88
87	NLRP3 inflammasome activation is required for fibrosis development in NAFLD. <i>Journal of Molecular Medicine</i> , 2014, 92, 1069-1082.	3.9	394
88	Caspase 3 Inactivation Protects Against Hepatic Cell Death and Ameliorates Fibrogenesis in a Diet-Induced NASH Model. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1197-1206.	2.3	98
89	Obesity, Nutrition, and Liver Disease in Children. <i>Clinics in Liver Disease</i> , 2014, 18, 219-231.	2.1	17
90	Leptin deficiency recapitulates the histological features of pulmonary arterial hypertension in mice. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 1935-46.	0.5	13

#	ARTICLE	IF	CITATIONS
91	From NAFLD to NASH to cirrhosis—new insights into disease mechanisms. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 627-636.	17.8	502
92	Serum Cytokeratin-18 Fragment Levels Are Useful Biomarkers for Nonalcoholic Steatohepatitis in Children. <i>American Journal of Gastroenterology</i> , 2013, 108, 1526-1531.	0.4	106
93	Combined paediatric <scp>NAFLD</scp> fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. <i>Liver International</i> , 2013, 33, 79-85.	3.9	86
94	Novel therapeutic targets for nonalcoholic fatty liver disease. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 773-779.	3.4	19
95	Circulating Levels of FGF-21 in Obese Youth: Associations With Liver Fat Content and Markers of Liver Damage. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2993-3000.	3.6	89
96	Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-8.	1.5	42
97	Lipid-Induced Toxicity Stimulates Hepatocytes to Release Angiogenic Microparticles That Require Vanin-1 for Uptake by Endothelial Cells. <i>Science Signaling</i> , 2013, 6, ra88.	3.6	177
98	Lysosomal Cathepsin D contributes to cell death during adipocyte hypertrophy. <i>Adipocyte</i> , 2013, 2, 170-175.	2.8	25
99	Oxidized metabolites of linoleic acid as biomarkers of liver injury in nonalcoholic steatohepatitis. <i>Clinical Lipidology</i> , 2013, 8, 411-418.	0.4	27
100	Caspase-1 as a Central Regulator of High Fat Diet-Induced Non-Alcoholic Steatohepatitis. <i>PLoS ONE</i> , 2013, 8, e56100.	2.5	154
101	Adipocyte hypertrophy is associated with lysosomal permeability both in vivo and in vitro: role in adipose tissue inflammation. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012, 303, E597-E606.	3.5	47
102	Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. <i>Laboratory Investigation</i> , 2012, 92, 713-723.	3.7	131
103	Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. <i>International Journal of Molecular Medicine</i> , 2012, 30, 49-56.	4.0	52
104	Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 152-161.	17.8	99
105	Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2012, 57, 1312-1318.	3.7	72
106	Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: New evidence on the potential therapeutic mechanism. <i>Hepatology</i> , 2012, 56, 1291-1299.	7.3	136
107	Lowering dietary linoleic acid reduces bioactive oxidized linoleic acid metabolites in humans. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2012, 87, 135-141.	2.2	153
108	Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2012, 32, 297-302.	3.9	207

#	ARTICLE	IF	CITATIONS
109	Inhibition of Apoptosis Protects Mice from Ethanol-Mediated Acceleration of Early Markers of Alcohol-Induced Fibrosis but not Steatosis or Inflammation. <i>Alcoholism: Clinical and Experimental Research</i> , 2012, 36, 1139-1147.	2.4	68
110	A Combination of the Pediatric NAFLD Fibrosis Index and Enhanced Liver Fibrosis Test Identifies Children With Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 150-155.e1.	4.4	90
111	Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011, 5, 201-212.	3.0	197
112	An apoptosis panel for nonalcoholic steatohepatitis diagnosis. <i>Journal of Hepatology</i> , 2011, 54, 1224-1229.	3.7	165
113	NASH animal models: Are we there yet?. <i>Journal of Hepatology</i> , 2011, 55, 941-943.	3.7	38
114	Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. <i>Nature</i> , 2011, 472, 57-63.	27.8	4,238
115	Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. <i>Journal of Digestive Diseases</i> , 2011, 12, 10-16.	1.5	76
116	Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial. <i>Hepatology</i> , 2011, 54, 1610-1619.	7.3	302
117	Ultrasonographic Quantitative Estimation of Hepatic Steatosis in Children With NAFLD. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2011, 53, 190-195.	1.8	227
118	Relations of Steatosis Type, Grade, and Zonality to Histological Features in Pediatric Nonalcoholic Fatty Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2011, 52, 190-197.	1.8	50
119	Identification of a Cytochrome P4502E1/Bid/C1q-dependent Axis Mediating Inflammation in Adipose Tissue after Chronic Ethanol Feeding to Mice. <i>Journal of Biological Chemistry</i> , 2011, 286, 35989-35997.	3.4	96
120	The Inflamed Liver and Atherosclerosis: A Link Between Histologic Severity of Nonalcoholic Fatty Liver Disease and Increased Cardiovascular Risk. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2644-2650.	2.3	99
121	High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. <i>Hepatology</i> , 2010, 52, 934-944.	7.3	311
122	Adipocyte Apoptosis, a Link between Obesity, Insulin Resistance, and Hepatic Steatosis. <i>Journal of Biological Chemistry</i> , 2010, 285, 3428-3438.	3.4	286
123	Severity of Liver Injury and Atherogenic Lipid Profile in Children With Nonalcoholic Fatty Liver Disease. <i>Pediatric Research</i> , 2010, 67, 665-670.	2.3	68
124	Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Journal of Lipid Research</i> , 2010, 51, 3046-3054.	4.2	237
125	Novel Insights into the Pathophysiology of Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2010, 30, 391-401.	3.6	106
126	Nonalcoholic steatohepatitis: risk factors and diagnosis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 623-635.	3.0	45

#	ARTICLE	IF	CITATIONS
127	Chronic Alcohol Exposure Increases Circulating Bioactive Oxidized Phospholipids. <i>Journal of Biological Chemistry</i> , 2010, 285, 22211-22220.	3.4	58
128	Autoimmune hepatitis in children—Impact of cirrhosis at presentation on natural history and long-term outcome. <i>Digestive and Liver Disease</i> , 2010, 42, 724-728.	0.9	55
129	Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study. <i>Hepatology</i> , 2009, 50, 1072-1078.	7.3	588
130	Nonalcoholic steatohepatitis in children: A multicenter clinicopathological study. <i>Hepatology</i> , 2009, 50, 1113-1120.	7.3	183
131	Diabetes Mellitus Is Associated with Impaired Response to Antiviral Therapy in Chronic Hepatitis C Infection. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2699-2705.	2.3	43
132	Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 445-451.	3.0	326
133	Retinol-Binding Protein 4: A Promising Circulating Marker of Liver Damage in Pediatric Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 575-579.	4.4	73
134	Hepatic Lipid Partitioning and Liver Damage in Nonalcoholic Fatty Liver Disease. <i>Journal of Biological Chemistry</i> , 2009, 284, 5637-5644.	3.4	359
135	Serum Retinol-binding Protein 4 Levels in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 985-989.	2.2	70
136	Severe Hepatocellular Injury With Apoptosis Induced by a Hepatitis C Polymerase Inhibitor. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 374-381.	2.2	25
137	The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. <i>Hepatology</i> , 2008, 47, 1495-1503.	7.3	242
138	Clinical Significance of Metabolic Syndrome in the Setting of Chronic Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 584-589.	4.4	52
139	Cytokeratin 18 Fragment Levels as a Noninvasive Biomarker for Nonalcoholic Steatohepatitis in Bariatric Surgery Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1249-1254.	4.4	149
140	Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis. <i>American Journal of Gastroenterology</i> , 2008, 103, 1372-1379.	0.4	531
141	Diagnosis of Nonalcoholic Fatty Liver Disease: Invasive versus Noninvasive. <i>Seminars in Liver Disease</i> , 2008, 28, 386-395.	3.6	257
142	Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future. <i>Hepatology</i> , 2007, 46, 582-589.	7.3	393
143	Reply:. <i>Hepatology</i> , 2007, 46, 2048-2048.	7.3	4
144	In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2006, 44, 27-33.	7.3	629

#	ARTICLE	IF	CITATIONS
145	Nonalcoholic fatty liver disease in the pediatric population: a review. <i>Current Opinion in Pediatrics</i> , 2005, 17, 636-641.	2.0	109
146	Apoptosis in alcoholic and nonalcoholic steatohepatitis. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 3093.	3.0	179
147	Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 384-389.	4.4	53
148	The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. <i>Gastroenterology</i> , 2005, 129, 113-121.	1.3	2,544
149	The Caspase Inhibitor IDN-6556 Attenuates Hepatic Injury and Fibrosis in the Bile Duct Ligated Mouse. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 1191-1196.	2.5	206
150	Steatohepatitis and Apoptosis: Therapeutic Implications. <i>American Journal of Gastroenterology</i> , 2004, 99, 1718-1719.	0.4	31
151	Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. <i>Hepatology</i> , 2004, 39, 909-914.	7.3	218
152	Free fatty acids promote hepatic lipotoxicity by stimulating TNF- $\alpha$ expression via a lysosomal pathway. <i>Hepatology</i> , 2004, 40, 185-194.	7.3	721
153	Primary sclerosing cholangitis in children: A long-term follow-up study. <i>Hepatology</i> , 2003, 38, 210-217.	7.3	218
154	Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. <i>Hepatology</i> , 2003, 38, 1188-1198.	7.3	398
155	Prevalence and clinical significance of human herpesviruses 6 and 7 active infection in pediatric liver transplant patients. <i>Pediatric Transplantation</i> , 2003, 7, 125-129.	1.0	54
156	Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. <i>Gastroenterology</i> , 2003, 125, 437-443.	1.3	948
157	Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. <i>Journal of Hepatology</i> , 2003, 39, 978-983.	3.7	294
158	Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolaemia. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 703-709.	0.7	49
159	Chronic Intestinal Pseudoobstruction Associated With Altered Interstitial Cells of Cajal Networks. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2003, 36, 492-497.	1.8	104
160	Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. <i>Journal of Clinical Investigation</i> , 2003, 112, 152-159.	8.2	176